Share Name Share Symbol Market Type Share ISIN Share Description
Vernalis LSE:VER London Ordinary Share GB00B3Y5L754 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.75p -9.43% 7.20p 7.04p 7.28p 7.80p 7.02p 7.72p 1,488,698 16:35:22
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.0 -15.3 -3.2 - 37.90

Vernalis Share Discussion Threads

Showing 3401 to 3424 of 3750 messages
Chat Pages: Latest  138  137  136  135  134  133  132  131  130  129  128  127  Older
DateSubjectAuthorDiscuss
12/10/2017
12:32
Looks.like.a fund raising coming judging by the lack of news and share price fall just like agl and nano . Expect it to level off jut above the issue price imo . So far looks like it could be at 8p or possibly 5p . Usual share price reaction when the company goes to the city asking for money no other real explanation I can see
bones698
12/10/2017
12:13
10p fund raising...........????????????
chrisdgb
09/10/2017
08:45
Is this worth buying? -priced almost like option money. Financially sound but massive cash burn. Any views from pharma expert?
meijiman
09/10/2017
08:30
Indeed, the big share holders need to get active with this one..........
chrisdgb
02/10/2017
15:22
Healthcare up across the board today with one exception - Vernalis. Time for a certain Mr. Woodford to insist on regime change at Vernalis?
romeike
28/9/2017
11:27
Is the incompetent CEO really considering a capital raise with the share price at rock bottom? Of course he is, he only cares about keeping his snout in the trough.
romeike
27/9/2017
12:32
brown envelopes all round for the directors and 'advisors' brown pants for the shareholders
pugg1ey
27/9/2017
12:02
SP here finding new lows as management fails to get to grips with major issues, fails to update shareholders with any good news and fails to revise its strategy. Why is Ian Garland still CEO?
romeike
17/9/2017
21:29
not quite sure what your point is hvs? was that suppose to be a dig at me? (best ignored judging by previous posts)
bountyhunter
16/9/2017
12:26
IDIOTS ABOUND and this is a bit too vague for my liking, again missing a target date other than sometime in 2018.. lol !!!!!! lol !!!!!!!!!!
hvs
12/9/2017
21:19
http://www.telegraph.co.uk/news/2017/09/12/nhs-fears-worst-flu-season-history/
romeike
12/9/2017
15:58
exactly, insufficient detail on this important matter given that Suir went into liquidation in May 2016 which is more than a year ago now
bountyhunter
12/9/2017
13:52
- the Company has progressed a new source of supply. Again this is all talking out the side of the mouth stuff. In all likelihood the company has not progressed anything other than negotiating with people who bought the old Suir assets (IQ Pharmatek) for them to continue to supply Moxatag under contract. The continuation of supply is not particularly interesting, what we want to know is what are the terms on which this drug is being supplied and will Vernalis actually make any significant margin on it. We await details but I would anticipate Vernalis is looking at a much reduced margin on this product.
romeike
12/9/2017
11:43
yes encouraging revenue increases but costs need to be reduced and should be some target dates on this bit imho... "We are also working closely with our partner Tris and the FDA to resubmit the NDAs for CCP-07 and CCP-08 as quickly as possible." and this is a bit too vague for my liking, again missing a target date other than sometime in 2018... "The previous manufacturer of Moxatag(R) , Suir, went into liquidation in May 2016. During the year, the Company has progressed a new source of supply and intends to manufacture Moxatag(R) in 2018."
bountyhunter
12/9/2017
08:36
So while revenues are indeed better than expected, mostly down to the research department, the company was less than upfront in its update when ir said costs would be below expected. As it turns out costs are up sharply at over 20mil. At the current rate of burn the company has only a few years before being forced to go back to market.
romeike
11/9/2017
12:47
Don't hold your breath for any new information tomorrow. There is still no FDA warning letters appearing for 2017 regarding Tris. Isn't it about time Vernalis let investors know what the hell is going on?
romeike
10/9/2017
07:24
Results due Tuesday.As important as the performance of Tuzistra will be clarification on the FDA relationship and a supply agreement for Moxatag.Is it too much to hope for?
fhmktg
01/9/2017
00:06
Wow! Mucho buying...... news on the way?
fhmktg
31/8/2017
19:30
With suspenders, you lucky man
ffp
31/8/2017
18:21
Somebody is stocking up!
fhmktg
22/8/2017
13:56
Share price propped up by bottom feeders. Not going to make any significant moves until a new strategy is made clear and we get some positive news. But yes, at least this isn't PFG of subprime vehicle finance fame - chances of recovery looking slim there. More likely it will end in administration.
romeike
22/8/2017
12:05
Like PFG another one of Woodford's. He's reputation surely in tatters now!!
barbar7619
16/8/2017
13:52
is that this year or next ;-)
bountyhunter
16/8/2017
11:50
If the last update is actually stuck to we should perhaps expect confirmation on 12 September that the sales force have begun active promotion of Moxatag®. I remain sceptical though :(
romeike
Chat Pages: Latest  138  137  136  135  134  133  132  131  130  129  128  127  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180623 12:08:54